Results 11 to 20 of about 10,523 (190)

PCSK9 Inhibitors [PDF]

Cell, 2016
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Pradeep, Natarajan, Sekar, Kathiresan
  +6 more sources

Safety of PCSK9 inhibitors

Biomedicine & Pharmacotherapy, 2022
annually in Europe, 4 million people die from cardiovascular diseases, the main cause of which is atherosclerosis. In order to slow down the development of atherosclerotic plaques, the main therapeutic goal is to lower LDL cholesterol (LDL-C) level. Undoubtedly, statins are the basis of lipid-lowering therapy for many years.
Grzegorz, Grześk, Bednarska, Dorota, Łukasz, Wołowiec, Anna, Wołowiec, Joanna, Osiak, Mariusz, Kozakiewicz, Joanna, Banach   +6 more
openaire   +2 more sources

Naturally Occurring PCSK9 Inhibitors [PDF]

Nutrients, 2020
Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotein (LDL) cholesterol levels.
Maria Pia Adorni, Francesca Zimetti, Maria Giovanna Lupo, Massimiliano Ruscica, Nicola Ferri   +4 more
openaire   +5 more sources

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism

Hepatology, EarlyView., 2022
Hepatic APOF transcript levels correlate inversely with plasma TG and hepatic steatosis in humans. ApoF expression in mice promotes VLDL‐TG production and lipoprotein remnant clearance in mice. Abstract Background NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD,
Audrey Deprince, Nathalie Hennuyer, Sander Kooijman, Amanda C. M. Pronk, Eric Baugé, Viktor Lienard, An Verrijken, Eveline Dirinck, Luisa Vonghia, Eloïse Woitrain, Niels J. Kloosterhuis, Eléonore Marez, Pauline Jacquemain, Justina C. Wolters, Fanny Lalloyer, Delphine Eberlé, Sandrine Quemener, Emmanuelle Vallez, Anne Tailleux, Mostafa Kouach, Jean‐Francois Goossens, Violeta Raverdy, Bruno Derudas, Jan Albert Kuivenhoven, Mikaël Croyal, Bart van de Sluis, Sven Francque, François Pattou, Patrick C. N. Rensen, Bart Staels, Joel T. Haas   +30 more
wiley   +1 more source

PCSK9 inhibitors

Swiss Medical Weekly, 2015
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces LDL receptor recycling, leading to a decrease of low-density lipoprotein cholesterol (LDL-C) receptors on the surface of hepatocytes and a subsequent increase of circulating LDL-C levels.
Gencer, B, Lambert, Gilles, Mach, François   +2 more
openaire   +8 more sources

PCSK9 inhibitors for hypercholesterolaemia [PDF]

BMJ, 2017
New drugs, old problems Statins (hydroxymethyl-glutaryl coenzyme A reductase inhibitors) reduce “bad” low density lipoprotein (LDL) cholesterol concentrations and cardiovascular risk. So too, do better diet and more exercise, which together almost halve rates of coronary event rates when compared with an “unfavourable lifestyle.”3 For some people ...
Patricia, McGettigan, Robin E, Ferner
openaire   +2 more sources

A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis [PDF]

Acta Pharmacologica Sinica
Wang WZ, Liu C, Luo JQ, Lei LJ, Chen MH, Zhang YY, Sheng R, Li YN, Wang L, Jiang XH, Xiao TM, Zhang YH, Li SW, Wu YX, Xu Y, Xu YN, Si SY.   +16 more
exaly   +2 more sources

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System

Cardiovascular Therapeutics, 2022
Background. Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). Objective.
Lingqing Ding, Congqin Chen, Yongkuan Yang, Jie Fang, Longxing Cao, Yige Liu   +5 more
doaj   +1 more source

The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia

Lipids in Health and Disease, 2021
Background As an autosomal dominant disorder, familial hypercholesterolemia (FH) is mainly attributed to disease-causing variants in the low-density lipoprotein receptor (LDLR) gene.
Haochang Hu, Ruoyu Chen, Yingchu Hu, Jian Wang, Shaoyi Lin, Xiaomin Chen   +5 more
doaj   +1 more source

PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases [PDF]

Терапевтический архив, 2018
Aim. We study the dynamics of oxidatively modified low-density lipoprotein (ox-LDL) content in blood plasma, as well as changes in the activity of key antioxidant enzymes such as Se-containing glutathione peroxidase (GSH-Px) Cu,Zn-superoxide dismutase ...
V Z Lankin, A K Tikhaze, M Viigimaa, I E Chazova   +3 more
doaj   +1 more source